The estimated Net Worth of St Co., Ltd Dong A is at least $20.1 Million dollars as of 23 June 2024. St A owns over 2,544,530 units of NeuroBo Pharmaceuticals Inc stock worth over $20,055,859 and over the last few years St sold NRBO stock worth over $0.
St has made over 1 trades of the NeuroBo Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently St bought 2,544,530 units of NRBO stock worth $7,964,379 on 23 June 2024.
The largest trade St's ever made was buying 2,544,530 units of NeuroBo Pharmaceuticals Inc stock on 23 June 2024 worth over $7,964,379. On average, St trades about 2,544,530 units every 0 days since 2024. As of 23 June 2024 St still owns at least 5,348,229 units of NeuroBo Pharmaceuticals Inc stock.
You can see the complete history of St A stock trades at the bottom of the page.
St's mailing address filed with the SEC is 64, CHEONHO-DAERO, DONGDAEMUN-GU, SEOUL, M5, 02587.
Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over $0 worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth $7,964,379 . The most active insiders traders include St Co., Ltd Dong A, Tae Heum Jeong, and Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of $9,541,988. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth $7,964,379.
neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.
NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include: